此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment (BEST)

2015年10月7日 更新者:Newcastle-upon-Tyne Hospitals NHS Trust

The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment After Their Neonatal Screen (BEST)

This study will look at the feasibility and acceptability of testing newborn babies who are referred after their newborn hearing screen for an infection called congenital Cytomegalovirus (cCMV). Around 1 in every 100 to 200 babies is born with this virus, and although most remain well it causes 1 in 5 cases of childhood deafness. Knowing that a baby is infected shortly after birth could have significant benefit since a treatment is now available, but screening programs need to be feasible and acceptable. This study aims to evaluate targeted screening for cCMV by taking samples (saliva and urine) from babies who do not pass their newborn hearing screening. The investigators want to see if we can find a quick, reliable and parentally acceptable way to screen babies who fail their hearing test for this virus.

研究概览

研究类型

观察性的

注册 (实际的)

411

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Tyne and Wear
      • Newcastle upon Tyne、Tyne and Wear、英国、NE1 4LP
        • Royal Victoria Infirmary, Newcastle Hospital NHS Trust

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 3周 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

This population this study examines is infants in Newcastle and South West London who are referred for more hearing tests after their neonatal hearing screen.

This cohort of patients will be offered screening tests for congenital CMV infection.

描述

Inclusion Criteria:

  • All infants 'referred' for one or both ears following hospital-based newborn hearing screening in North of Tyne and South West London areas. Babies with other known causes of SNHL (e.g. hereditary) and those admitted to Neonatal Intensive Care Units will be included.

Exclusion Criteria:

  • Exclusions to this study will be infants with parents/guardians not willing/able to give informed consent or children known to have congenital CMV by antenatal testing or clinical features of CMV infection at birth.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Babies referred for further hearing tests
Babies referred for further hearing tests after their neonatal hearing screening tests
With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Feasibility of targeted screening for congenital CMV
大体时间:30 months
Feasibility: as determined by proportion of urine and salivary swabs processed with a result back to parents and health professionals that would allow treatment if needed to be initiated by 28 days of age.
30 months
Acceptability of extended screening tests
大体时间:30 months
Parental acceptability as determined by anxiety measures (in comparison to published data in parents whose infants are referred for failing their hearing screen, but where no mention of extended screening is made) and parental responses to extended questionnaires about the ease of the process of obtaining samples.
30 months

次要结果测量

结果测量
措施说明
大体时间
Clinical utility of extended screening tests
大体时间:30 months

Secondary outcomes.

Assess and compare the clinical utility of performing salivary and urine CMV testing on babies referred through NHSP in terms of:

  1. rate of diagnosis of cCMV by day 21
  2. rate of initiation of treatment, where clinically indicated, by 4 weeks of age. 2. Calculate the prevalence of cCMV in children with SNHL detected following newborn hearing screening (number per population screened)
30 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Julia Clark、Newcastle-upon-Tyne Hospitals NHS Trust
  • 首席研究员:Janet Berrington、Newcastle-upon-Tyne Hospitals NHS Trust
  • 首席研究员:Mike Sharland、St Georges Healthcare Trust
  • 首席研究员:Suzanne Luck、Royal Free Hospital NHS Foundation Trust

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年8月1日

初级完成 (实际的)

2013年2月1日

研究完成 (实际的)

2013年2月1日

研究注册日期

首次提交

2010年7月13日

首先提交符合 QC 标准的

2010年7月13日

首次发布 (估计)

2010年7月14日

研究记录更新

最后更新发布 (估计)

2015年10月12日

上次提交的符合 QC 标准的更新

2015年10月7日

最后验证

2015年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • 5286
  • 10/H0904/25 (其他标识符:REC)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅